Structural Heart Disease

WASHINGTON — Women with symptomatic severe aortic stenosis had better 1-year outcomes after transcatheter aortic valve replacement vs. surgery, according to a pooled analysis of only women in the PARTNER 3 low-risk and RHEIA trials.

AISAP announced the FDA granted 510(k) clearance for its first-in-class, AI-powered point-of-care ultrasound software platform for the measurement of several cardiac pathologies.

ATLANTA — A screening study presented at the American College of Cardiology Scientific Session showed that there is a high prevalence of unrecognized heart disease among former National Football League players.

A consensus statement outlines best practices and competencies for cardiac catheterization in pediatric patients and adults with congenital heart disease, reflecting an evolution in practice for patients with unique procedural requirements.

Eko announced the launch of a digital stethoscope that includes the use of artificial intelligence to identify structural heart murmurs.

Eko Technologies announced the FDA has cleared its next-generation software for detecting and identifying heart murmurs in adult and pediatric patients.

This year marks 2 decades since the first transcatheter aortic valve replacement procedure was performed on an inoperable patient with severe symptomatic aortic stenosis — a historic moment that would change interventional cardiology.

Transcatheter tricuspid valve repair system (Pascal, Edwards Lifesciences) for patients with tricuspid regurgitation.

The Society for Cardiovascular Angiography and Interventions published its recommendations for percutaneous placement of large-bore arterial sheaths and devices specifically via transaxillary arterial access.

Head-to-head comparison of two LAA closure devices (Amplatzer Amulet, Abbott, and Watchman FLX or 2.5, Boston Scientific).